After stepping down as CEO of X (formerly Twitter), Linda Yaccarino has taken on a new leadership role as CEO of eMed Population Health, a digital health startup focused on supporting patients using GLP-1 medications like Ozempic for weight management and type 2 diabetes.
Yaccarino, a former advertising executive at NBCUniversal, spent two years at X navigating a turbulent period marked by advertiser exits and controversial platform changes under Elon Musk. Despite lacking direct experience in health tech, eMed cited her “undeniable ability to negotiate new partnerships” and her high-profile tech industry presence as key reasons for her appointment.
eMed initially developed a platform for guiding users through at-home COVID-19 testing. Now, it is pivoting toward chronic condition management using GLP-1 therapies, aiming to revolutionize preventative healthcare through AI-driven solutions.
In a statement, Yaccarino said:
To be a leader in today’s healthcare marketplace, companies need fearless tenacity, not just to grow, but to redefine the industry. We are well-positioned to be that leader, improving global healthcare outcomes through our groundbreaking services and platforms.
